Additional file 2: Figure S2. of Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases

AD0157 reduces LYVE-1 mRNA expression in mammary tumors and in draining LNs. Analyses of LYVE-1 expression by qRT-PCR, normalized to GADPH expression, in mammary MDA-MB-231/Luc+ tumors and LNs resected from control and AD0157-treated mice. Values are expressed as mean ± s.e.m. and Wilcoxon-Mann-Whitney significance tests were used to compare the differences between control and AD0157 treatments. *p